Sales challenges were also at the forefront of Salesforce’s "State of Sales Report 2024 2 " which surveyed over 5,500 sales professionals and identified that the number one top priority for sales ...

Despite meeting key pharmacokinetic goals, a potential case of drug-induced liver injury led Pfizer to conclude that danuglipron’s risk-benefit profile did not support further development for chronic ...

Approval of Opdivo plus Yervoy combination was based on results from the Phase III CheckMate-9DW trial, which demonstrated ...

Odylia Therapeutics event brings together leaders across biotech, pharma, venture capital, patient advocacy, and research ...

Commerce Secretary Lutnick discussed the state of the tariffs in the wake of President Trump’s comments on the pharmaceutical and electronics industries.

Marketing and sales personnel who leverage the expertise and insights of MedAffairs can often have better success.

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, explains how Juvena plans to differentiate JUV-112 from other obesity therapeutics targeting adipose tissue.

The Verseon CEO discusses how this advanced technology is helping to discover new drug candidates.

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses how the "multiple confidential discussions" ...

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.

Full approval of Vitrakvi was based on results from three clinical trials in patients with unresectable or metastatic NTRK ...

In the Phase III ICONIC-LEAD trial, 75% of adolescents with moderate-to-severe plaque psoriasis treated with icotrokinra ...